Clinical trials: Squamous Head and Neck Carcinoma
Head and Neck Cancer
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and saliva from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898300
- Testing
- biologic sample preservation procedure, biopsy
- Where
- 98 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Radiation Therapy Oncology Group
Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms
The Diagnostic Value of PET/MRI in Head and Neck Cancer
This study investigates the diagnostic value of PET/MRI for cervical lymph node metastases from head and neck squamous cell carcinomas.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymph Node Metastases
- Trial name
- NCT04117139
- Testing
- PET/MRI
- Where
- Denmark
- Volunteers
- 142 people
- Sponsor
- Odense University Hospital
Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Head &Amp;Amp; Neck Squamous Cell Carcinoma
Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
Delays between surgery and the initiation of post-operative radiotherapy (S-PORT) in head and neck cancer (HNC) patients are prevalent and associated with worse oncologic outcomes.
- Conditions
- Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Head &Amp;Amp; Neck Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
- Trial name
- PRONTO-HN (NCT07180901)
- Testing
- Proactive Risk-Based Optimization and Notifications for Treatment and Outcomes (PRONTO)
- Where
- Canada
- Volunteers
- 85 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
HNSCC, Head and Neck Neoplasms
A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy
Open, multicenter, single arm, phase II, biomarker driven umbrella trial for head and neck squamous cell carcinoma (FGFR inhibitor, CDK4/6 inhibitor, pan HER inhibitor, PI3K inhibitor, PD1/PD-L1 inhibitor)
- Trial name
- NCT03356587
- Testing
- Abemaciclib
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Seoul National University Hospital
HPV-Related Oropharynx Squamous Cell Carcinoma
The Minimalist Trial-2
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA.
- Trial name
- MINT-2 (NCT06702033)
- Testing
- Radiation therapy, Cisplatin, Surgery
- Where
- 3 sites in United States
- Volunteers
- 142 people
- Sponsor
- Washington University School of Medicine
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Neoplasms, Hiv
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
This study evaluates whether the Potlako+ intervention of community education, clinical provider support, and patient navigation can improve access to cancer case for patients presenting with symptoms of cancer.
- Conditions
- Neoplasms, Hiv, Cervical Cancer, Breast Cancer
- Trial name
- Potlako+ (NCT04141449)
- Testing
- Potlako intervention, Enhanced care
- Where
- Botswana
- Volunteers
- 874 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
- Trial name
- NCT04154943
- Testing
- Cemiplimab
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Regeneron Pharmaceuticals
Head and Neck Squamous Cell Carcinoma
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell…
- Trial name
- ELEVATE HNSCC (NCT04854499)
- Testing
- Magrolimab, Pembrolizumab, Docetaxel
- Where
- 88 sites in United States, Australia and 9 more
- Volunteers
- 193 people
- Sponsor
- Gilead Sciences
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Surgical resection is currently the major treatment for esophageal carcinoma while disease progression still occurred in most cases within 3 years.
- Trial name
- NCT04390958
- Testing
- nab-paclitaxel, Cisplatin, Capecitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese Academy of Medical Sciences
Head and Neck Cancer
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
- Trial name
- NCT00304278
- Testing
- Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), Radiation Therapy (RAD)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Southern Illinois University
Squamous Cell Carcinoma of the Head and Neck
Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to determinate the free-progression interval in patients with surgically resected locally advanced squamous cell carcinoma of head and neck treated with the maximum tolerated dose of the combination of…
- Trial name
- NCT00442455
- Testing
- Erlotinib chlorhydrate, Cisplatin, Radiation therapy
- Where
- 5 sites in Spain
- Volunteers
- 53 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Primary Non-operated Squamous Cell Carcinoma of Oral Cavity, Primary Non-operated Squamous Cell Carcinoma of Oropharynx
Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer.
The investigators hypothesize that treatment adaptation to biological and anatomical changes, occurring during treatment, can increase the chance of cure at minimized or equal radiation-induced toxicity in head and neck cancer…
- Conditions
- Primary Non-operated Squamous Cell Carcinoma of Oral Cavity, Primary Non-operated Squamous Cell Carcinoma of Oropharynx, Primary Non-operated Squamous Cell Carcinoma of Hypopharynx, Primary Non-operated Squamous Cell Carcinoma of Larynx
- Trial name
- C-ART-2 (NCT01341535)
- Testing
- Adaptive dose-painting-by-numbers, standard intensity-modulated radiotherapy (IMRT)
- Where
- 2 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Head and Neck Neoplasms, Recurrent Disease
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell…
- Conditions
- Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
- Trial name
- NCT05260671
- Testing
- Penpulimab combined with cetuximab
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01064921
- Testing
- vorinostat, cisplatin, radiation therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Stage IV Esophagus Squamous Cell Carcinoma
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
To observe and evaluate the efficacy and safety of camrelizumab combined with chemotherapy or anlotinib in patients with advanced esophageal squamous cell carcinoma previously Treated With First-line Immunotherapy
- Trial name
- NCT05322499
- Testing
- Camrelizumab, Irinotecan, Paclitaxel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.